| __timestamp | Iovance Biotherapeutics, Inc. | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2704597 | 7459000 |
| Thursday, January 1, 2015 | 15470000 | 11831000 |
| Friday, January 1, 2016 | 28037000 | 25705000 |
| Sunday, January 1, 2017 | 71615000 | 46181000 |
| Monday, January 1, 2018 | 99828000 | 59497000 |
| Tuesday, January 1, 2019 | 166023000 | 65003000 |
| Wednesday, January 1, 2020 | 201727000 | 74506000 |
| Friday, January 1, 2021 | 259039000 | 126006000 |
| Saturday, January 1, 2022 | 294781000 | 126215000 |
| Sunday, January 1, 2023 | 344077000 | 120161000 |
Cracking the code
In the ever-evolving world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Iovance Biotherapeutics, Inc. has consistently outpaced Protagonist Therapeutics, Inc. in R&D investment. From 2014 to 2023, Iovance's R&D expenses surged by over 12,000%, peaking at approximately $344 million in 2023. In contrast, Protagonist's R&D spending grew by around 1,500%, reaching about $120 million in the same year.
This significant difference highlights Iovance's aggressive pursuit of innovation, potentially positioning it as a leader in the biotech sector. Meanwhile, Protagonist's steady growth reflects a more conservative approach. As the industry continues to advance, these spending patterns may influence each company's ability to bring groundbreaking therapies to market, ultimately impacting their competitive standing.
R&D Insights: How Eli Lilly and Company and Protagonist Therapeutics, Inc. Allocate Funds
R&D Spending Showdown: Sarepta Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.
TG Therapeutics, Inc. or Iovance Biotherapeutics, Inc.: Who Invests More in Innovation?
Research and Development Investment: ADMA Biologics, Inc. vs Protagonist Therapeutics, Inc.
R&D Insights: How CymaBay Therapeutics, Inc. and Protagonist Therapeutics, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Apellis Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc.
Analyzing R&D Budgets: Apellis Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.
Analyzing R&D Budgets: Perrigo Company plc vs Protagonist Therapeutics, Inc.
Analyzing R&D Budgets: Perrigo Company plc vs Iovance Biotherapeutics, Inc.
ImmunityBio, Inc. or Protagonist Therapeutics, Inc.: Who Invests More in Innovation?
R&D Spending Showdown: Protagonist Therapeutics, Inc. vs Xencor, Inc.
R&D Insights: How Iovance Biotherapeutics, Inc. and Travere Therapeutics, Inc. Allocate Funds